• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

Smarter™ 4th Generation CAR Design Services

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

As the leading biotech provider for CAR-T related therapeutic research, Creative Biolabs invested a lot of manpower and material resources to innovate and develop new immunotherapy technologies. Based on years of experiences and experiments, scientists from Creative Biolabs are now able to provide the latest CAR technology services, Smarter™ Technology for 4^th Generation CAR.

Background

Most Chimeric Antigen Receptors (CARs) are comprised of an antigen-binding domain of a single chain variable fragment (scFv), a transmembrane region and an intracellular signal transduction domain. CAR-engineered T cell therapy is one of the most effective and comprehensive anticancer therapies, which has been developing rapidly in recent years. The artificial CARs can be used to enhance the specificity of engineered T cell. The CAR-T cells harbor stronger properties in targeting, activity and durability than immunocytes of conventional application.

The CAR technology has evolved from the first generation to third generation. First generation CAR only contains the CD3ζ intracellular signaling domain, which is later proven to limit T cell persistence and efficacy in preclinical studies. To overcome these lmitations, the second and third generation CARs incorporate the intracellular signaling domains from various costimulatory molecules. For example, the second-generation CAR may contain CD3ζ and CD28 domains, and the third-generation CAR may include CD3ζ, CD28 and other signaling domains such as OX-40 or 4-1BB. T cells expressing these later generation CARs have shown that they improved persistence, activation and efficacy of CAR-T cells in clinical studies. However, there are still some adverse effects following the CAR-T cells therapy, such as cytokine storm and on-target/off-tumor effect.

In order to overcome these adverse effects, Creative Biolabs focuses on developing new CAR technologies. After years of research and testing, we have developed the latest CAR technology - Smarter™ Technology for 4^th Generation CAR. The Smarter^TM CARs express certain domains to promote or regulate the activity of CAR-T cells, or prevent toxicity, which improves the safety and efficacy of CAR-T cell therapy. The categories of Smarter^TM CARs include armoured CAR, self-destruct CAR, conditional CAR, marked CAR, dual CAR and safety CAR. Compared with the other triditional CARs, the Smarter^TM CARs exhibit significant safety and efficacy. Creative Biolabs provides a whole set of service including but not limit to the construction of CAR, vector packaging, CAR manufacture, T cell engineering, in vitro and in vivo test of Smarter^TM CAR-T cells.

Advantages of Smarter™ CAR family